COVID-19 disease first emerged as a presentation of severe respiratory infection in Wuhan, China in late 2019 (WHO, 2020). By January 2020, lower respiratory samples taken from affected patients were sequenced and demonstrated a novel coronavirus (SARS-CoV-2) (Huang et al, 2020). The first two cases in the UK were seen in late January (Lillie et al, 2020). In March 2020, the World Health Organization (WHO) declared a SARS-CoV-2 pandemic (WHO Director-General, 2020).

SARS-CoV-2 is a member of the family of Coronaviridae and genus Betacoronavirus (Zhu et al, 2020). Phylogenetic analysis of SARS-CoV-2 has shown that it is genetically distinct from the SARS coronavirus (Dhama, et al, 2020), but appears to share strong sequence similarity to bat coronaviruses in China (Lam et al, 2020).

As with other coronaviruses, SARS-CoV-2 is an RNA virus which encodes four major structural proteins, spike (S), membrane (M), envelope (E) and a helical nucleocapsid (N) (Dhama et al, 2020). The S glycoprotein is considered the main antigenic target and consists of an S1 and S2 subunit (Kaur et al, 2020). The S1 subunit has two functional domains: the N terminal domain (NTD) and receptor binding domain (RBD) which contains the receptor binding motif (RBM) (Kaur et al, 2020). The RBM binds to angiotensin converting enzyme 2 (ACE2) on host cells and is endocytosed with subsequent release of the viral genome into the cytoplasm (Amanat et al, 2020).

SARS-CoV-2 is primarily transmitted by person to person spread through respiratory aerosols, direct human contact and fomites (Kaur et al, 2020). Estimates of the basic reproduction number [R] were initially between 2 and 3 although a recent estimate was as high as 5.7 (Sanche et al, 2020). This high transmissibility indicates that stringent control measures, such as active surveillance, physical distancing, early quarantine and contact tracing, are needed in order to control viral spread. Perinatal transmission has been reported although the exact transmission route has not been elucidated (ECDC, 2020).

After the initial exposure, patients typically develop symptoms within 5-6 days (incubation period) although about 20% of patients remain asymptomatic throughout infection (Cevik et al, 2020). Polymerase chain reaction (PCR) tests can detect viral SARS-CoV-2 RNA in the upper respiratory tract for a mean of 17 days, although transmission is maximal in the first week of illness. Symptomatic and pre-symptomatic transmission (1-2 days before symptom onset), is thought to play a greater role in the spread of SARS-CoV-2 than asymptomatic transmission.
The disease

In adults, the clinical picture varies widely. A significant proportion of individuals are likely to have mild symptoms and may be asymptomatic at the time of diagnosis.

Symptoms are commonly reported as a new onset of cough and fever (Grant et al, 2020), but may include headache, loss of smell, nasal obstruction, lethargy, myalgia (aching muscles), rhinorrhea (runny nose), taste dysfunction, sore throat, diarrhoea, vomiting and confusion; fever may not be reported in all symptomatic individuals. Patients may also be asymptomatic (He et al, 2020).

Progression of disease, multiple organ failure and death will occur in some individuals (Pachetti et al, 2020).

Currently available data suggest that increasing age and male gender are significant risk factors for severe infection. However, there are also groups of patients with underlying comorbidities, where infection may result in increased risk of serious disease (Docherty et al, 2020). In a large review of primary care records pseudonymously linked with SARS-CoV-2 status, comorbidities including diabetes, cancer and poorly controlled asthma were associated with increased risk of death (Williamson et al, 2020).

Infection fatality ratios (IFR) for COVID-19 in the UK, derived from combining mortality data with infection rates in seroprevalence studies, show a marked increase in IFR in the oldest age groups (Table 1) (Ward et al, 2020).

In Europe and the UK, deaths attributed to SARS-CoV-2 have been reported disproportionately from residential care homes (ECDCb, 2020, Graham et al 2020). Other notable risk groups include healthcare workers (Nguyen et al, 2020) who may acquire infection both in the hospital or within the community setting (Bielicki et al, 2020). Current evidence suggests that deprivation and being from black and asian minority ethnic groups results in a higher risk for death from SARS-CoV-2 infection (Williamson et al, 2020), although the factors that contribute to this are not yet clear.
Table 1: UK Infection fatality ratio and estimated total numbers of deaths (February to July 2020)

<table>
<thead>
<tr>
<th>Category</th>
<th>Population Size</th>
<th>SARS-CoV-2 antibody prevalence% (95% CI)</th>
<th>Confirmed COVID-19 deaths</th>
<th>Infection fatality ratio % (95% CI)</th>
<th>Estimated number of infections (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>56,286,961</td>
<td>6.0 (5.7, 6.8)</td>
<td>30180</td>
<td>0.9 (0.9, 0.9)</td>
<td>3,362,037 (3,216,816; 3,507,258)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>27,827,831</td>
<td>6.5 (5.8, 6.6)</td>
<td>18575</td>
<td>1.1 (1.0, 1.2)</td>
<td>1,729,675 (1,614,585; 1,844,766)</td>
</tr>
<tr>
<td>Female</td>
<td>28,459,130</td>
<td>5.8 (5.4, 6.1)</td>
<td>11600</td>
<td>0.7 (0.7, 0.8)</td>
<td>1,633,785 (1,539,821; 1,727,749)</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15-44</td>
<td>21,335,397</td>
<td>7.2 (6.7, 7.7)</td>
<td>524</td>
<td>0.0 (0.0, 0.0)</td>
<td>1,535,884 (1,436,941; 1,634,826)</td>
</tr>
<tr>
<td>45-64</td>
<td>14,405,759</td>
<td>6.2 (5.8, 6.6)</td>
<td>4657</td>
<td>0.5 (0.5, 0.5)</td>
<td>895,238 (837,231; 953,244)</td>
</tr>
<tr>
<td>65-74</td>
<td>5,576,066</td>
<td>3.2 (2.7, 3.7)</td>
<td>5663</td>
<td>3.1 (2.6, 3.6)</td>
<td>181,044 (153,426; 208,661)</td>
</tr>
<tr>
<td>75+</td>
<td>4,777,650</td>
<td>3.3 (2.5, 4.1)</td>
<td>19330</td>
<td>11.6 (9.2, 14.1)</td>
<td>166,077 (131,059; 200,646)</td>
</tr>
</tbody>
</table>

1 All estimates of prevalence adjusted for imperfect test sensitivity and specificity (see text for details). Responses have been re-weighted to account for differential sampling (geographic) and for variation in response rate (age, gender, ethnicity and deprivation) in final column to be representative of the England population (18+).

2 Infection fatality ratios were calculated excluding care home residents. Confirmed COVID-19 death counts were obtained from https://fingertips.phe.org.uk/static-reports/mortality-surveillance/excess-mortality-in-England-week-ending-17-jul-2020.html. Deaths in care homes by age on 12 June 2020 were obtained from www.ons.gov.uk. Total deaths in care home residents up to 17 July 2020 were obtained from www.ons.gov.uk. The age stratified estimates of COVID-19 deaths were then estimated using the total deaths from 17 July and the age distribution from 12 June. We assumed that age distribution of deaths did not change between 12 June and 17 July 2020.
**Children**

Fewer than 5% of COVID-19 cases are amongst children and in general they appear to exhibit mild disease. Although cough and fever are the main symptoms in children (Ladhani et al., 2020), a UK study tracking children of healthcare workers has recently shown that of those who were seropositive, gastrointestinal symptoms were also commonplace (Waterfield et al., 2020). Preliminary evidence suggested that not only do children have a lower susceptibility to SARS-CoV-2 infection, but they are also unlikely to be key drivers of transmission at a population level (Viner et al., 2020). However, a recent prospective study found higher secondary attack rates where the household index case was a child (Lopez Bernal et al., 2020).

A spectrum of multi system inflammatory disease similar to Kawasaki disease (KD) was recently described in children admitted during the SARS-CoV-2 pandemic, temporally associated with severe acute respiratory syndrome attributed to SARS-CoV-2 (Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS)) (Whittaker et al., 2020). This severe presentation in children is extremely rare, but appears to encompass a wide range of features, including fever, gastrointestinal symptoms, rash, myocardial injury and shock (Swann et al., 2020).

**Pregnant women and neonates**

The risk to pregnant women and neonates following COVID-19 infection is generally low: more than half of pregnant women who test positive for SARS-CoV-2 are asymptomatic, and although stillbirth and neonatal death remain very rare, some UK studies have suggested a high rate of stillbirth in infected women (Allotey et al., 2020, Gurol-Urganci et al., 2021). It is still unclear whether SARS-CoV-2 can be transmitted vertically, and only about 2% of neonates born to COVID-positive mothers in the UK test positive for SARS-CoV-2 in the first 12 hours of life (Vousden et al., 2021). However, the risk of preterm birth is increased two to threefold for women with symptomatic COVID-19 (Vousden et al., 2021), usually as a result of a medical recommendation to deliver early to improve maternal oxygenation.\(^1\) Furthermore, a small proportion of pregnant women can have severe or fatal COVID-19. The largest global systematic review indicates that pregnant women are more likely to be admitted to the intensive care unit (ICU) with COVID-19 than age-matched non-pregnant women, (Mullins et al., 2021) and there is a signal that this is true in the UK as well.\(^2\)

Pregnant women are more likely to have severe COVID-19 infection if they are overweight or obese, are of black and asian minority ethnic background, have co-morbidities such as diabetes, hypertension and asthma, or are 35 years old or older (Vousden et al., 2021, Allotey et al., 2020).

**COVID-19 vaccines**

The recognition of the pandemic has accelerated the development and testing of several vaccines using platforms investigated during previous emergencies such as the SARS pandemic (Amanat et al., 2020) and Ebola in West Africa. Candidate vaccines include nucleic acid vaccines, inactivated virus vaccines, live attenuated vaccines, protein or peptide subunit vaccines, and viral-vectored vaccines.

---

1 NICE Guideline 25, 2019 [https://www.nice.org.uk/guidance/ng25](https://www.nice.org.uk/guidance/ng25)
2 [https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports](https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports)
Most vaccine candidates focus on immunisation with the spike (S) protein, which is the main target for neutralising antibodies. Neutralising antibodies that block viral entry into host cells through preventing the interaction between the spike protein Receptor Binding Motif (RBM) and the host cell Angiotensin-converting enzyme 2 (ACE2) are expected to be protective (Addetia et al., 2020, Thompson et al., 2020).

In the UK four vaccines targeting the S protein have been authorised for supply; two use an mRNA platform (Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2 or Comirnaty® and Moderna mRNA-1273 COVID-19 vaccine or Spikevax®) and two use an adenovirus vector (AstraZeneca COVID-19 vaccine / Vaxzevria® and COVID-19 vaccine Janssen Ad26. COV2-S [recombinant]).

The Pfizer BioNTech and Moderna COVID-19 vaccines are nucleoside-modified messenger RNA (mRNA) vaccines. mRNA vaccines use the pathogen’s genetic code as the vaccine; this then exploits the host cells to translate the code and then make the target spike protein. The protein then acts as an intracellular antigen to stimulate the immune response (Amanat et al., 2020). mRNA is then normally degraded within a few days. Both the Moderna mRNA-1273 and the Pfizer BioNTech COVID-19 BNT162b2 vaccines have been generated entirely in vitro and are formulated in lipid nanoparticles which are taken up by the host cells (Vogel et al., 2020, Jackson et al., 2020). The Pfizer vaccine was tested in healthy adults between the ages of 18-55 and 65-85 years in phase 1 studies and the BNT162b2 vaccine product at a 30 µg dose was chosen by Pfizer as the lead candidate in phase 2/3 trials (Walsh et al., 2020). The Moderna mRNA-1273 vaccine was tested at three dose levels in those aged 18-55 years and the 100µg dose chosen for phase 3 study (Jackson et al., 2020).

AstraZeneca COVID-19 vaccine uses a replication deficient chimpanzee adenovirus (ChAd) as a vector to deliver the full-length SARS-CoV2 spike protein genetic sequence into the host cell (Van Doremalen et al., 2020). The adenovirus vector is grown in a human cell-line (HEK293) (see chapter 1). ChAd is a non-enveloped virus; the glycoprotein antigen is not present in the vector, but is only expressed once the genetic code within the vector enters the target cells. The vector genes are also modified to render the virus replication incompetent, and to enhance immunogenicity (Garafalo et al., 2020). Once the vector is in the nucleus, mRNA encoding the spike protein is produced that then enters the cytoplasm. This then leads to translation of the target protein which acts as an intracellular antigen.

**Vaccine effectiveness**

**Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2 (Comirnaty®)**

Two doses of Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2 successfully reduced the levels of detectable viral RNA in Rhesus macaques when followed by intra-nasal and intra-tracheal challenge with SARS-CoV-2 (Vogel et al., 2020). In phase 1/2 human trials, after prime and boost vaccination, neutralising antibodies were comparable or higher than in convalescent patients. Neutralising antibody responses were generally higher in the 18 to 55 year age group compared to the 65 to 85 year age group, but responses were comparable to levels in convalescent patients in both age groups.

A phase 3 study was conducted in around 44,000 individuals aged 12 years and above with a second dose delivered between 19 and 42 days. Initial analysis conducted as part of a phase 3 study demonstrated a two-dose vaccine efficacy of 95% (with credibility intervals from 90.3% to 97.6%) in those aged 16 years and above. Efficacy was consistent across age, gender, and ethnicity, and in the presence of co-morbidities (including asthma,
obesity, diabetes, hypertension and lung disease). In naïve participants aged between 65 and 75 years, and in those aged 75 years and over, the efficacy was 94.7% (95% CI 66.7-99.9%) and 100% (95% CI 13.1-100%) respectively. Efficacy remained high when the analysis included those with evidence of prior immunity. Published efficacy between dose 1 and 2 of the Pfizer vaccine was 52.4% (95% CI 29.5-68.4%). Based on the timing of cases accrued in the phase 3 study, most vaccine failures in the period between doses occurred shortly after vaccination, suggesting that short term protection from dose 1 is very high from day 10 after vaccination (Polack et al, 2020). Using data for those cases observed between day 15 and 21, efficacy against symptomatic COVID-19 after the first dose was estimated at 89% (95% CI 52-97%). (https://www.fda.gov/media/144246/download)

The Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2 received approval to supply in the UK from the Medicine and Healthcare products Regulatory Agency (MHRA) on 2 December 2020. Following an additional study in over 2000 children aged 12-15 years, which generated additional safety and efficacy data, the approval was extended to those in this age group in June 2021.

In September 2021, the MHRA approved the use of Pfizer BioNTech vaccine as a third or reinforcing dose, at least eight weeks after completion of a primary course of either an mRNA or adenovirus vectored vaccine.

AstraZeneca COVID-19 vaccine (Vaxzevria®)

AstraZeneca COVID-19 vaccine elicited increased neutralisation antibodies in Rhesus macaques as well as a reduction in detectable virus in the lower respiratory tract following challenge with SARS-CoV-2 (Van Doremalen et al, 2020). In phase 1/2 human trials AstraZeneca COVID-19 vaccine was compared with a meningococcal conjugate vaccine (MenACWY) control in healthy adults aged between 18-55 years (Folegatti et al, 2020). Preliminary findings showed that neutralising antibodies were induced at day 14 and 28 after the first vaccination and titres increased after a second dose. Specific T cell responses were also induced after a single immunisation and were maintained after the second dose. Final data showed that IgG spike antibody responses and neutralising antibody 28 days after the second dose were similar across the three age cohorts (18–55 years, 56–69 years, and ≥70 years). More than 99% (208/209) of the participants had neutralising antibody responses two weeks after the second dose. Peak T-cell responses were seen 14 days after the first dose and were broadly equivalent in the three age groups (Ramasamy et al, 2020). In analysis of over 11,000 patients in the phase 3 study, overall vaccine efficacy against symptomatic disease was 70·4% (95% CI: 54·8–80·6%) (Voysey et al, 2020). There were ten cases hospitalised for COVID-19, of which two were severe, all in the control group, suggesting very high protection against severe disease. High protection against hospitalisation was seen from 21 days after dose 1 until two weeks after the second dose, suggesting that a single dose will provide high short term protection against severe disease (Voysey et al, 2020). An exploratory analysis of participants who had received one standard dose of the vaccine suggested that efficacy against symptomatic COVID-19 was 73.00% (95% CI: 48.79-85.76%).

The AstraZeneca COVID-19 vaccine received approval to supply in the UK from the MHRA on 30 December 2020.

In September 2021, the MHRA approved the use of AstraZeneca vaccine as a third or reinforcing dose, at least eight weeks after completion of a primary course of AstraZeneca vaccine.
Moderna COVID-19 vaccine (Spikevax®)

In phase 1 testing of the Moderna mRNA-1273 vaccine, all patients seroconverted to IgG by Enzyme-Linked Immunosorbent Assay (ELISA) after the first dose of vaccine. Pseudo-neutralisation and wild virus neutralisation responses were detected in all participants after two 100µg doses of the Moderna mRNA-1273. Phase 3 placebo controlled testing in over 30,000 volunteers, showed a vaccine efficacy of 94.1% (95% CI: 89.3-96.8%). Efficacy was similar in those over 65 years. Vaccine efficacy against severe COVID-19 was 100% (95% CI: 87.0-100%) (Baden et al., 2020).

The cumulative case numbers in the phase 3 study showed a clear divergence between the vaccine and placebo groups from about 14 days after the first dose. Re-analysis of the phase 3 data from 15 days after the first dose to the time of the second dose, suggested that efficacy of a single dose was 92.1% (95% CI 68.8%-99.1%).

The Moderna vaccine (Spikevax®) was approved for use in the UK in January 2021. Following a study in over 3000 children aged 12-17 years, which generated additional safety and efficacy data, the approval was extended to those in this age group in August 2021.

Real world effectiveness

Vaccine effectiveness data from the UK are now emerging. A single dose of either the Pfizer-BioNTech or the AstraZeneca vaccines has been shown to provide around 60% protection against symptomatic disease; vaccinated cases are also around 40% less likely to require hospital admission or to die (Lopez Bernal et al, 2021a). This is consistent with protection of around 80% against hospitalisation as seen in local studies (Vasileiou et al., 2021, AvonCAP, 2021).

Protection against infection has also been seen in healthcare workers, where a single dose of Pfizer vaccine provided more than 70% protection against both symptomatic and asymptomatic infection (Hall et al, 2021a), and in care home residents where a single dose of either Pfizer or AstraZeneca vaccines reduced the risk of infection by around 60% (Shroti et al, 2021). The observed reduction in both symptomatic and asymptomatic infections suggests that vaccination has potential to reduce transmission; this was supported by a Scottish study that showed a 30% reduction in risk of infection in the household members of vaccinated compared to unvaccinated healthcare workers after a single dose of the Pfizer BioNTech vaccine. (Shah et al., 2021).

Higher levels of protection are observed after the second dose for both Pfizer BioNTech (Lopez Bernal et al, 2021b) and AstraZeneca vaccines. A summary of the most recent data on real world effectiveness is now published on a weekly basis. https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports

Following the introduction of the Delta variant to the UK in April 2021, further updates to the analysis of real world effectiveness have been undertaken (Lopez Bernal et al, 2021b). The latest data suggest that protection against Delta is slightly lower than against Alpha, particularly after a single dose. Protection against hospitalisation, however, is maintained with two doses of the AstraZeneca and Pfizer BioNTech vaccines providing over 90% protection against this outcome. (Stowe et al, 2021).
Duration of protection

Israel was the first country to demonstrate waning protection from Pfizer BioNTech vaccine showing a decline in protection, even against severe disease, at around 6 months (Goldberg et al, 2021). In the USA, protection against hospitalisation for Pfizer BioNTech and Moderna vaccines remained high (around 84%) between 3 and 6 months (Tenforde et al, 2021).

Updated UK analysis to late August 2021 suggests that protection against symptomatic infection due to the Delta variant appears to decline after the second dose, although remains above 50% overall after 5 months. (Andrews et al, 2021) Levels of protection from AstraZeneca are lower than that seen after Pfizer BioNTech and remain around 20% lower after 5 months. In contrast, protection against hospitalisation and death appears to be well sustained, remaining over 95% at five months for PfizerBioNTech. Although early protection against hospitalisation starts high (above 90%), there is a suggestion of a decline with estimates of around 80% protection against hospitalization at five months. This decline appears to be mainly driven by older people (over 65 years) and those with clinical risk factors (including immunosuppression).

Safety

Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2 (Comirnaty®)

Local reactions at the injection site are fairly common after Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2, primarily pain at the injection site, usually without redness and swelling. Systemic events reported were generally mild and short lived (Walsh et al, 2020). In the final safety analysis of over 21,000 participants 16 years and older, the most common events were injection site pain (>80%), fatigue (>60%), and headache (>50%). Myalgia, arthralgia and chills were also common with fever in 10-20%, mainly after the second dose. Most were classified as mild or moderate. Lymphadenopathy in the axillary, supraclavicular or cervical nodes on the same side as the injection was reported in less than 1% (Polack et al, 2020).

Four cases of Bell’s palsy were reported in vaccine recipients in the trial. Although within the expected background rate, this will be monitored closely post-implementation.

Side effects were less common in those aged over 55 than those aged 16 to 55 years. Severe systemic effects, defined as those that interfere with daily activity, included fatigue in 4% and headache in 2%. There was no signal to suggest that prior vaccination led to enhanced disease with only 1 case of severe COVID-19 in the 8 vaccine failures (Polack et al, 2020).

Recently a number of cases of myocarditis and pericarditis have been reported after Pfizer BioNTech vaccine. The reported rate appears to be highest in those under 25 years of age and in males, and after the second dose. Onset is within a few days of vaccination and most cases are mild and have recovered without any sequelae. The MHRA has advised the benefits of vaccination still outweigh any risk in most individuals.

A very small number of cases of Guillain-Barré Syndrome (GBS) have been reported after Pfizer-BioNTech vaccination but these reports have not reached the number expected to occur by chance in the immunised population.

Moderna COVID-19 vaccine (Spikevax®)

A high proportion (more than 75%) of vaccine recipients had localised pain at the injection site after both dose 1 and dose 2 of the Moderna mRNA-1273 vaccine. Redness and swelling were also seen after the second dose and local pain tended to last longer (around 3 days). Mild systemic effects were also common, including headache, fatigue, joint and
muscle aches and chills. Systemic events were more severe after dose 2 and fever was only seen after dose 2, and both local and systemic reactions were less common in older participants (Baden et al., 2020). Adverse events were less common in those with pre-existing SARS-CoV-2 antibody. Axillary lymphadenopathy on the same side as the injection site was detected in more than one in ten recipients.

Bell’s palsy was reported by three participants in the vaccine group and one participant in the placebo group. As for the Pfizer vaccine, this will be monitored closely post-implementation. There were no cases of severe COVID-19 disease in the vaccine group, and thus no signal for enhanced disease (Baden et al., 2020).

Recently a number of cases of myocarditis and pericarditis have been reported after Moderna vaccine. The reported rate appears to be highest in those under 25 years of age and in males, and after the second dose. Onset is within a few days of vaccination and most cases are mild and have recovered without any sequelae. The MHRA has advised the benefits of vaccination still outweigh any risk in most individuals.

A very small number of cases of GBS have been reported after Moderna vaccination but these reports have not reached the number expected to occur by chance in the immunised population.

AstraZeneca COVID-19 vaccine (Vaxzevria®)

From early phase trials, mild pain and tenderness at the injection site was common with AstraZeneca COVID-19 vaccine occurring in 88% of 18-55 year olds, 73% of 56-69 year olds and 61% of people aged 70 years or over; similar levels were reported after each dose. Short lived systemic symptoms including fatigue and headache were also common but decreased with age, being reported in 86%, 77%, and 65% of those aged 18-55, 56-69 and 70 years or over respectively; most of these were classified as mild or moderate. These reactions were unusual after the second dose (Ramasamy et al., 2020). Mild fever (>38˚C) was recorded in the first 48 hours for around a quarter of younger participants but was not reported in those over 55 years of age or in any age group after the second dose (Ramasamy et al., 2020). Fever can be modified by the prophylactic use of paracetamol, which does not affect the immune response to this vaccine (Folegatti et al., 2020). In the phase 3 study, injection site reactions, mild fever, headache, myalgia and arthralgia occurred in more than 10% of vaccinees. Less than 1% reported lymphadenopathy or an itchy rash. Only one serious adverse event was reported as possibly linked to the vaccine; this was a case of transverse myelitis which occurred 14 days after dose 2. There was no signal to suggest that prior vaccination led to enhanced disease (Voysey et al., 2020).

A very rare condition involving serious thromboembolic events accompanied by thrombocytopenia, has been reported after AstraZeneca vaccination. The condition presents with unusual venous thrombosis, including cerebral sinus thrombosis, portal vein thrombosis, and sometimes arterial thrombosis, with low platelet count and high D-dimer measurements. The condition has similarities to heparin-induced thrombocytopenia and thrombosis (HITT or HIT type 2) and patients usually have positive antibody to platelet factor 4. The majority of the events occurred between 5 and 16 days following vaccination (Greinacher et al., 2021).

The current reported rate of this event in the UK is around 15 cases per million after the first dose, although a higher incidence is seen in younger individuals. After the second dose the reported rate is much lower, particularly in younger individuals. Overall, the Joint
Committee on Vaccination and Immunisation (JCVI), MHRA and the WHO remain clear that the benefits of vaccination outweigh this small risk for adults aged 40 years and over, adults who are clinically extremely vulnerable and those with underlying clinical risks as defined in table 3.

GBS has been reported very rarely within six weeks of AstraZeneca vaccination, and rates appear to be higher than the background rates. This risk would equate to about 5.6 extra cases of GBS per million doses in the six weeks following the first dose of AstraZeneca vaccine, based on an unpublished UK study. There was no evidence of a higher rate of reporting in individuals who had had a previous episode of GBS.

A small number of cases of capillary leak syndrome have been reported across Europe within 4 days of AstraZeneca vaccination. Around half of those affected had a history of capillary leak syndrome.

**Reinforcing immunisation**

Studies of boosting in the UK have shown that a third dose of AstraZeneca, Moderna and Pfizer BioNTech vaccines successfully boosted individuals who had been primed with two doses of Pfizer BioNTech or AstraZeneca vaccine around 3 months earlier. Levels of IgG and pseudoneutralising antibody, including against Delta variant, were generally higher where an mRNA vaccine was used as either a heterologous or homologous boost, or where AstraZeneca was used as a heterologous boost after a primary course of Pfizer BioNTech. Levels of antibody after an AstraZeneca boost in those primed with the same vaccine are as good or better than those seen after the second dose; these antibody levels correlate with high levels of protection against severe disease and death. This finding was confirmed in a study where a third dose of AstraZeneca was given at a later time point (Flaxman et al, 2021).

All boosters led to short term local and systemic reactions, similar to those seen after the primary course, including local pain, fatigue, headache and muscle pain. Rates of reactions were higher with heterologous than homologous boosters and in those aged under 70 years when compared to older recipients. Rates of local and systemic symptoms were higher where a full dose of Moderna was used to boost those who had received either AstraZeneca or Pfizer BioNTech for the primary course and when AstraZeneca was used to boost those who had Pfizer BioNTech as a primary course, when compared to Pfizer BioNTech after either primary vaccination.

A separate study using a half dose of Moderna (50mcg) in those who had received a primary course of Moderna (100mcg) showed good immunogenicity and a rate of reactions similar to the second dose of Moderna. (Choi et al, 2021).

In Israel, administration of a booster dose of Pfizer BioNTech to adults who had received a primary course of the same vaccine, has been associated with a major reduction in the risk of both confirmed and severe disease due to COVID-19. (Bar-On et al 2021)

**Storage**

The Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2 should be stored in a freezer at -80°C to -60°C (-90ºC to -60ºC in the thermal container). Shelf life is 6 months at -80°C to -60°C. Frozen vials should be transferred to 2°C to 8°C to thaw; a 195 vial pack may take 3 hours to thaw. Alternatively, frozen vials may also be thawed for 30 minutes at temperatures up to 25°C for immediate use.
After thawing, stability data have demonstrated that undiluted vaccine can be stored for up to 31 days at 2°C to 8°C. Once thawed, the vaccine cannot be re-frozen.

The AstraZeneca vaccine should be stored at 2°C to 8°C and has a shelf life of 6 months. The vaccine does not contain any preservative. After first opening the vial, it should be used within 6 hours. The vaccine may be stored between 2°C and 25°C during this period. After this time, the vial must be discarded.

Moderna COVID-19 vaccine vials should be stored frozen between -25°C to -15°C and have a shelf life of 7 months at these temperatures. Once thawed, the vaccine may be stored refrigerated at 2°C to 8°C protected from light for up to 30 days if not punctured. The unopened vial is stable for 12 hours at 8° to 25°C.

**Presentation**

Each pack of the Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2 (Comirnaty®) contains 195 vials with a minimum of 6 doses per vial (975 doses per pack). It is supplied with 0.9% sodium chloride diluent for injection in plastic ampoules. After dilution, the vaccine should be kept at 2°C to 25°C and used within 6 hours. Any unused vaccine should be discarded.

The AstraZeneca vaccine is supplied in packs of 10 vials. Each vial contains 8 or 10 doses of vaccine, and is a colourless to slightly brown, clear to slightly opaque liquid.

Moderna COVID-19 vaccine is supplied in multidose vials containing 10 doses of 0.5ml.

**Dosing and schedule**

**All COVID-19 vaccines**

For both adenovirus vector and mRNA vaccines, there is evidence of better immune response and/or protection where longer intervals between doses in the primary schedule are used. (Amirthalingam et al 2021, Payne et al, 2021, Voysey et al 2021).

Based on this evidence, longer intervals are likely to provide more durable protection. JCVI is currently recommending a minimum interval of eight weeks between doses of all the available COVID-19 vaccines where a two-dose primary schedule is used for adults and for children at high risk (see section on children). Operationally, using the same minimum interval for all products will simplify supply and booking, and will help to ensure a good balance between achieving rapid and long-lasting protection.

For those under 18 who are not in a high risk group a 12 week interval is preferred. This is based on precautionary advice from the JCVI based on emerging evidence of a lower rate of myocarditis in countries that use a longer schedule.

The main exception to the eight week lower interval would be those about to commence immunosuppressive treatment. In these individuals, the minimal intervals outlined below may be followed to enable the vaccine to be given whilst their immune system is better able to respond.

**Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2 (Comirnaty®)**

The dose of Pfizer BioNTech COVID-19 vaccine is 30µg contained in 0.3ml of the diluted vaccine. After dilution each multidose vial can be used to deliver six doses of 0.3ml.

The primary course should be administered in two doses, a minimum of 21 days apart.
AstraZeneca COVID-19 vaccine (Vaxzevria®)

The dose of AstraZeneca COVID-19 vaccine is 0.5ml.

The primary course should be administered in two doses, a minimum of 4 weeks apart.

Moderna COVID-19 vaccine (Spikevax®)

The dose of Moderna COVID-19 vaccine is 0.5ml.

The primary course should be administered in two doses, a minimum of 28 days apart.

In August 2021, JCVI recommended a third primary dose of vaccination for individuals who were severely immunosuppressed when they received their first or second dose of COVID-19 vaccination (see below).

Administration

Vaccines are routinely given intramuscularly into the upper arm or anterolateral thigh. This is to reduce the risk of localised reactions, which are more common when vaccines are given subcutaneously (Mark et al., 1999; Zuckerman, 2000; Diggle and Deeks, 2000).

Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2 (Comirnaty®) should be administered as an intramuscular injection into the deltoid muscle. A 1ml syringe with a 23g x 25mm needle will be provided for administration. A separate needle and syringe should be used for each individual. The vial should be discarded if the solution is discoloured or visible particles are observed.

AstraZeneca COVID-19 vaccine (Vaxzevria®) is administered as a single dose of 0.5ml intramuscular injection into the deltoid muscle. A 1ml syringe with a 23g/25g x 25mm needle will be provided for administration. The vaccine should be inspected visually for particulate matter and discolouration prior to administration. The vial should be discarded if the solution is discoloured or visible particles are observed. The vial should not be shaken. A separate needle and syringe should be used for each individual. It is normal for liquid to remain in the vial after withdrawing the final dose.

Moderna COVID-19 vaccine (Spikevax®) should be administered as an intramuscular injection into the deltoid muscle. A 1ml syringe with a 23g x 25mm needle will be provided for administration. A separate needle and syringe should be used for each individual. It is normal for liquid to remain in the vial after withdrawing the final dose.

Individuals with bleeding disorders may be vaccinated intramuscularly if, in the opinion of a doctor familiar with the individual’s bleeding risk, vaccines or similar small volume intramuscular injections can be administered with reasonable safety by this route. If the individual receives medication/treatment to reduce bleeding, for example treatment for haemophilia, intramuscular vaccination can be scheduled shortly after such medication/treatment is administered. Individuals on stable anticoagulation therapy, including individuals on warfarin who are up-to-date with their scheduled INR testing and whose latest INR is below the upper level of the therapeutic range, can receive intramuscular vaccination. A fine needle (23 or 25 gauge) should be used for the vaccination, followed by firm pressure applied to the site without rubbing for at least 2 minutes (Advisory Committee on Immunization Practices 2019). The individual/parent/carer should be informed about the risk of haematoma from the injection.
Disposal

Equipment used for vaccination, including used vials, ampoules or syringes, should be disposed of by placing them in a proper, puncture-resistant ‘sharps box’ according to local authority regulations and guidance in Health Technical Memorandum 07-01: Safe management of healthcare waste (Department of Health, 2013).

AstraZeneca COVID-19 vaccine (Vaxzevria®) contains genetically modified organisms (GMOs). Sharps waste and empty vials should be placed into yellow lidded waste bins and sent for incineration; there is no need for specific designation as GMO waste. An appropriate virucidal disinfectant should be available for managing spills in all settings where vaccination is administered. Potentially contaminated gloves and aprons can be disposed in yellow/black striped bags for offensive waste.

The COVID-19 immunisation programme

The objectives of the COVID-19 immunisation programme is to protect those who are at highest risk from serious illness or death. The JCVI ranked the eligible groups according to risk. For the first phase this was based on the risk of COVID-19 specific mortality, with the second phase concerned with prevention of hospitalisation.

Phase 1 recommendations for primary vaccination

Evidence from the UK indicates that the risk of poorer outcomes from COVID-19 infection increases dramatically with age in both healthy adults and in adults with underlying health conditions. Those over the age of 65 years have by far the highest risk, and the risk increases with age. Residents in care homes for older adults have been disproportionately affected by the COVID-19 pandemic. Table 2 sets out JCVI advice on priority groups for primary COVID-19 vaccination. Table 3 sets out JCVI advice on clinical and other risk groups for COVID-19 vaccination.

Table 2 – Phase 1 priority groups for primary vaccination advised by the Joint Committee on Vaccination and Immunisation

<table>
<thead>
<tr>
<th>Priority group</th>
<th>Risk group</th>
</tr>
</thead>
</table>
| 1              | Residents in a care home for older adults  
                | Staff working in care homes for older adults |
| 2              | All those 80 years of age and over  
                | Frontline health and social care workers |
| 3              | All those 75 years of age and over |
| 4              | All those 70 years of age and over  
                | Individuals aged 16 to 69 in a high risk group¹ |
| 5              | All those 65 years of age and over |
| 6              | Adults aged 16 to 65 years in an at-risk group (Table 3) |
| 7              | All those 60 years of age and over |
| 8              | All those 55 years of age and over |
| 9              | All those 50 years of age and over |

¹ Previously known as clinically extremely vulnerable
People at high risk (priority groups 4 and 6)

People previously defined as clinically extremely vulnerable (CEV) were considered to be at high risk of severe illness from COVID-19 (https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19#cev); and these patients were flagged on the GP system. A hospital clinician or GP was able to add a patient to the list, based on their clinical judgement, because they considered them to be at very high risk of serious illness from COVID-19.

All patients who were on the CEV list also fell into the broader disease categories outlined in table 3, but were vaccinated with priority group 4 because of more recent treatment, more advanced condition or co-morbidities.

Table 3: Clinical and other risk groups for individuals aged 16 years and over eligible for phase 1 primary COVID-19 immunisation.

<table>
<thead>
<tr>
<th>Clinical risk groups</th>
<th>Individuals with a severe lung condition, including those with poorly controlled asthma¹ and chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema; bronchiectasis, cystic fibrosis, interstitial lung fibrosis, pneumoconiosis and bronchopulmonary dysplasia (BPD).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic respiratory disease</td>
<td>Congenital heart disease, hypertension with cardiac complications, chronic heart failure, individuals requiring regular medication and/or follow-up for ischaemic heart disease. This includes individuals with atrial fibrillation, peripheral vascular disease or a history of venous thromboembolism.</td>
</tr>
<tr>
<td>Chronic heart disease and vascular disease</td>
<td>Chronic kidney disease at stage 3, 4 or 5, chronic kidney failure, nephrotic syndrome, kidney transplantation.</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>Cirrhosis, biliary atresia, chronic hepatitis.</td>
</tr>
<tr>
<td>Chronic liver disease</td>
<td>Stroke, transient ischaemic attack (TIA). Conditions in which respiratory function may be compromised due to neurological or neuromuscular disease (e.g. polio syndrome sufferers). This group also includes individuals with cerebral palsy, severe or profound and multiple learning disabilities (PMLD), Down’s syndrome, multiple sclerosis, epilepsy, dementia, Parkinson’s disease, motor neurone disease and related or similar conditions; or hereditary and degenerative disease of the nervous system or muscles; or severe neurological disability.</td>
</tr>
<tr>
<td>Chronic neurological disease</td>
<td>Any diabetes, including diet-controlled diabetes, current gestational diabetes, and Addison’s disease.</td>
</tr>
</tbody>
</table>

¹ Poorly controlled asthma is defined as:
- ≥2 courses of oral corticosteroids in the preceding 24 months OR
- on maintenance oral corticosteroids OR
- ≥1 hospital admission for asthma in the preceding 24 months
| **Immunosuppression** | Immunosuppression due to disease or treatment, including patients undergoing chemotherapy leading to immunosuppression, patients undergoing radical radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients, HIV infection at all stages, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID).

Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil.

Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day for adults.

Anyone with a history of haematological malignancy, including leukaemia, lymphoma, and myeloma.

Those who require long term immunosuppressive treatment for conditions including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, scleroderma and psoriasis.

Some immunosuppressed patients may have a suboptimal immunological response to the vaccine (see Immunosuppression and HIV).

| **Asplenia or dysfunction of the spleen** | This also includes conditions that may lead to splenic dysfunction, such as homozygous sickle cell disease, thalassemia major and coeliac syndrome.

| **Morbid obesity** | Adults with a Body Mass Index (BMI) $\geq 40$ kg/m$^2$.

| **Severe mental illness** | Individuals with schizophrenia or bipolar disorder, or any mental illness that causes severe functional impairment.

| **Younger adults in long-stay nursing and residential care settings** | Many younger adults in residential care settings will be eligible for vaccination because they fall into one of the clinical risk groups above (for example learning disabilities). Given the likely high risk of exposure in these settings, where a high proportion of the population would be considered eligible, vaccination of the whole resident population is recommended. Younger residents in care homes for the elderly will be at high risk of exposure, and although they may be at lower risk of mortality than older residents should not be excluded from vaccination programmes (see priority 1 above).

| **Other risk groups** | Individuals who expect to share living accommodation on most days (and therefore for whom continuing close contact is unavoidable) with individuals who are immunosuppressed (defined as above).

| **Adult carers** | Those who are eligible for a carer’s allowance, or those who are the sole or primary carer of an elderly or disabled person who is at increased risk of COVID-19 mortality and therefore clinically vulnerable.$^1$

---

$^1$ Those clinically vulnerable to COVID-19 are defined by the JCVI priority groups: a) children of any age with severe neuro-disability, severe or profound and multiple learning disabilities (including Down’s syndrome and those on the learning disability register) or immunosuppression (as defined in table 4), b) adults who have underlying health conditions leading to greater risk of disease or mortality as defined in table 3, c) those of advanced age.
The examples above are not exhaustive, and, within these groups, the prescriber should apply clinical judgment to take into account the risk of COVID-19 exacerbating any underlying disease that a patient may have, as well as the risk of serious illness from COVID-19 itself. A list of eligible diagnoses, and the appropriate clinical codes, can be found in the link at the end of the chapter.

**Recommendations by staff groups**

The objective of occupational immunisation of health and social care staff is to protect workers at high risk of exposure who may also expose vulnerable individuals whilst providing care. There is increasing evidence that vaccination will lead to a reduction in transmission, and even a small effect will have major additional benefit for staff who could expose multiple vulnerable patients and other staff members. Potential exposure to COVID-19, and therefore the priority for vaccination, may vary from workplace to workplace. Therefore, it is recommended that these staff groups are offered primary vaccination against COVID-19 as outlined below.

**Frontline healthcare staff**

This includes the following groups:

**Staff involved in direct patient care**

This includes staff who have frequent face-to-face clinical contact with patients and who are directly involved in patient care in either secondary or primary care/community settings. This includes doctors, dentists, midwives and nurses, paramedics and ambulance staff, pharmacists, optometrists, occupational therapists, physiotherapists and radiographers. It should also include those working in independent, voluntary and non-standard healthcare settings such as hospices, and community-based mental health or addiction services. Staff working on the COVID-19 vaccination programme, temporary staff, students, trainees and volunteers who are working with patients must also be included.

**Non-clinical staff in secondary or primary care/community healthcare settings**

This includes non-clinical ancillary staff who may have social contact with patients but are not directly involved in patient care. This group includes receptionists, ward clerks, porters and cleaners.

**Laboratory and pathology staff**

Hospital-based laboratory and mortuary staff who frequently handle SARS-CoV-2 or collect or handle potentially infected specimens, including respiratory, gastrointestinal and blood specimens should be eligible as they may also have social contact with patients. This may also include cleaners, porters, secretaries and receptionists in laboratories. Frontline funeral operatives and mortuary technicians/embalmers are both at risk of exposure and likely to spend a considerable amount of time in care homes and hospital settings where they may also expose multiple patients.

Staff working in non-hospital-based laboratories and those academic or commercial research laboratories who handle clinical specimens or potentially infected samples will be able to use effective protective equipment in their work and should be at low risk of exposure, and of exposing vulnerable patients.
Frontline social care workers

This includes front-line social care workers who provide care closely and regularly to those who are clinically vulnerable. Those clinically vulnerable to COVID-19 are defined by the JCVI priority groups: a) children of any age with severe neuro-disability, severe or profound and multiple learning disabilities (including Down’s syndrome and those on the learning disability register) or immunosuppression (as defined in table 4), b) adults who have underlying health conditions leading to greater risk of disease or mortality as defined in table 3, c) those of advanced age. This includes:

- those working in long-stay residential and nursing care homes or other long-stay care facilities where rapid spread is likely to follow introduction of infection and cause high morbidity and mortality
- social care staff directly involved in the care of clinically vulnerable patients or clients
- others involved directly in delivering social care such that they and clinically vulnerable patients/clients are at increased risk of exposure

Young people age 16-17 years, who are employed in, studying or in training for health and social care work should be offered a full course of primary vaccination alongside their colleagues, if a suitable vaccine is available (see section on age specific recommendations). Younger people who are taking part in health and social care work as volunteers, interns or for the purposes of work experience, should make all efforts to avoid exposure to infection; they should be offered vaccination in line with other under 16s (see below).

Phase 2 advice

The objectives of the second phase of the COVID-19 immunisation programme is to also protect those who are at risk from serious illness or death, and to protect the NHS by reducing the risks of hospitalisation and critical care admission. Phase 2 of the programme should therefore be accompanied by continued efforts to maximise coverage amongst those prioritised in Phase 1 but who remain unvaccinated, and to complete delivery of second doses to all those given first doses in Phase 1.

There is good evidence that the risks of hospitalisation and critical care admission from COVID-19 increase with age. JCVI therefore advised that the offer of vaccination during Phase 2 is age-based starting with the oldest adults first. As there is an increased risk of hospitalisation in males, those from certain ethnic minority backgrounds, those who are obese or morbidly obese, and those from socio-economically deprived areas, JCVI advises that specific focus should be used to promote and deliver vaccination to the following groups:

All those aged 40-49 years
All those aged 30-39 years
All those aged 18-29 years
Young people aged 16-17 years

Young people aged 16-17 years at higher risk

Young people aged 16 to 17 years who are in a recognised clinical risk group (see table 3) and those who work in health and social care should receive two doses of vaccine at an interval of at least eight weeks. This includes those aged 16 to 17 years who expect to share living accommodation on most days (and therefore for whom continuing close contact is unavoidable) with individuals of any age who are immunosuppressed (defined in tables 3 and 4).

Other young people aged 16-17 years

JCVI have recommended that young people aged 16-17 years who are not in a risk group should receive their first dose of vaccine. A second dose of vaccine should be offered after an interval of at least 12 weeks. This longer interval reflects the strong evidence of high levels of protection against severe disease from the first dose, and emerging evidence that countries with longer schedules may have a lower rate of myocarditis after the second dose. Although this latter evidence is limited, JCVI have taken a precautionary approach to mitigate the very rare risk of post-vaccine myocarditis. Young people should be fully informed about the benefits and risks of the second dose and able to discuss the optimal timing for them.

Children and young people aged 12-15 years

Children and young people at higher risk of severe COVID-19

Children and young people aged 12 to 15 years who are in recognised risk groups (table 4) should receive two doses of Pfizer vaccine at an interval of at least eight weeks. Although children are at low overall risk from the complications of COVID-19 infection, the JCVI has reviewed available evidence on children who may be at higher risk. Initially, based on clinical reviews and analysis of primary care data (Williamson et al, 2021), JCVI had advised that children with severe neuro-disabilities, immunosuppression, Down’s Syndrome, profound and multiple learning disabilities (PMLD), severe learning disabilities or who are on the learning disability register, should be offered COVID-19 vaccination. Recently completed analysis under an expert group commissioned by the Deputy Chief Medical Officer has identified a number of distinct diagnostic groups with a high absolute risk (greater than 100/million) of paediatric intensive care admission over the 2020-21 period. These groups include children with haematological malignancy, Sickle cell disease, Type 1 diabetes, and congenital heart disease (Harwood et al, 2021, Smith et al, 2021, Ward et al, 2021). For most other diagnostic groups, such as renal and liver disease, the numbers of cases admitted or the size of the population were too small to generate a robust estimate of risk. The exception to this was asthma where the rate of admission was only slightly raised above the rate in healthy children, suggesting that, in line with the evidence from adults, only poorly controlled asthma constitutes a clinical risk for the complications of COVID-19 infection. In addition to these distinct diagnoses, the analysis suggested that the admission rate was high in a pooled group of children with chronic conditions. This basket of chronic conditions included any health problem requiring follow-up by health services in most affected children, as used for a Royal College of Paediatrics and Child Health review of mortality in 2013. The conditions included involved diagnoses in each of the main organ systems and therefore, based on this analysis, JCVI decided that vaccine should be offered to similar groups as those prioritised for adult vaccination with the exception of obesity and mental illness. JCVI decided that most major underlying health conditions would

1 https://www.rcpch.ac.uk/sites/default/files/CHR-UK_-_Retrospective_Epidemiological_Review_of_All-cause_Mortality_in_CYP.pdf
reasonably apply to children and young people (summarised in Table 4). Children aged over 12 years with these conditions are often severely affected by other respiratory infections and should therefore be offered a course of COVID-19 vaccination.

**Individuals aged 12 to 15 years who are contacts of immunosuppressed individuals**
Those aged 12 years and above who expect to share living accommodation on most days (and therefore for whom continuing close contact is unavoidable) with individuals of any age who are immunosuppressed (defined in tables 3 and 4) should be offered two doses of vaccine eight weeks apart.

**Other children and young people aged 12-15 years**

A decision on when to offer the second dose to children and young people who are not at high risk is pending further evidence on the safety of a second dose in this age group.
Table 4: Clinical risk groups for children aged 12-15 years

<table>
<thead>
<tr>
<th>Category</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic respiratory disease</td>
<td>Including those with poorly controlled asthma(^1) that requires continuous or repeated use of systemic steroids or with previous exacerbations requiring hospital admission, cystic fibrosis, ciliary dyskinesias and bronchopulmonary dysplasia.</td>
</tr>
</tbody>
</table>
| Chronic heart conditions                      | Haemodynamically significant congenital and acquired heart disease, or less severe heart disease with other co-morbidity. This includes:  
  - single ventricle patients or those palliated with a Fontan (Total Cavopulmonary Connection) circulation  
  - those with chronic cyanosis (oxygen saturations <85% persistently)  
  - patients with cardiomyopathy requiring medication  
  - patients with congenital heart disease on medication to improve heart function  
  - patients with pulmonary hypertension (high blood pressure in the lungs) requiring medication. |
| Chronic conditions of the kidney, liver or digestive system | Including those associated with congenital malformations of the organs, metabolic disorders and neoplasms, and conditions such as severe gastrooesophageal reflux that may predispose to respiratory infection. |
| Chronic neurological disease                  | This includes those with  
  - neuro-disability and/or neuromuscular disease including cerebral palsy, autism, epilepsy and muscular dystrophy  
  - hereditary and degenerative disease of the nervous system or muscles, other conditions associated with hypoventilation  
  - severe or profound and multiple learning disabilities (PMLD), Down’s syndrome, those on the learning disability register  
  - neoplasm of the brain |
| Endocrine disorders                            | Including diabetes mellitus, Addison’s and hypopituitary syndrome. |
| Immunosuppression                              | Immunosuppression due to disease or treatment, including:  
  - those undergoing chemotherapy or radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients  
  - genetic disorders affecting the immune system (e.g. deficiencies of IRAK-4 or NEMO, complement disorder, SCID)  
  - those with haematological malignancy, including leukaemia and lymphoma  
  - those receiving immunosuppressive or immunomodulating biological therapy  
  - those treated with or likely to be treated with high or moderate dose corticosteroids  
  - those receiving any dose of non-biological oral immune modulating drugs e.g. methotrexate, azathioprine, 6-mercaptopurine or mycophenolate  
  - those with auto-immune diseases who may require long term immunosuppressive treatments |
| Asplenia or dysfunction of the spleen          | Including hereditary spherocytosis, homozygous sickle cell disease and thalassemia major. |
| Serious genetic abnormalities that affect a number of systems | Including mitochondrial disease and chromosomal abnormalities. |

\(^1\) Poorly controlled asthma is defined as:  
- ≥2 courses of oral corticosteroids in the preceding 24 months OR  
- on maintenance oral corticosteroids OR  
- ≥1 hospital admission for asthma in the preceding 24 months  
Third primary dose for those aged 12 years or over

Some individuals who are immunosuppressed due to underlying health conditions or medical treatment may not mount a full immune response to primary COVID-19 vaccination. Preliminary results from UK studies of real-world vaccine effectiveness (VE) in persons who are immunosuppressed suggest only a modest reduction in VE against symptomatic COVID-19 (Whitaker et al., 2021). Immunogenicity studies measuring binding or neutralising antibody and/or cellular responses have suggested that, amongst the immunosuppressed group, some individuals with more severe forms of immunosuppression make low or no detectable responses. A few published studies describing the effect of a third dose of mRNA vaccine in persons who are immunosuppressed report increased immune responses in varying proportions of persons. (Hall et al. 2021b, Kamar et al. 2021, Werbel et al. 2021).

Although there are no known correlates of protection against infection, symptomatic disease and severe COVID-19 (hospitalisation and deaths), JCVI considers that a small group of immunosuppressed individuals should be offered a third primary vaccination.

JCVI advises that a third vaccine dose be offered to individuals aged 12 years and over who had severe immunosuppression in proximity to their first or second COVID-19 doses in the primary schedule (Box). Most individuals whose immunosuppression commenced at least two weeks after the second dose of vaccination do not require an additional primary vaccination at this stage.

The decision on the timing of the third dose should be undertaken by the specialist involved in the care of the patient. In general, vaccines administered during periods of minimum immunosuppression (where possible) are more likely to generate better immune responses.

The third dose should be given ideally at least 8 weeks after the second dose, with special attention paid to current or planned immunosuppressive therapies. Where possible the third dose should be delayed until two weeks after the period of immunosuppression, in addition to the time period for clearance of the therapeutic agent. If not possible, consideration should be given to vaccination during a treatment ‘holiday’ or when the degree of immunosuppression is at a minimum. Advice for patients on chemotherapy is available at https://www.ukchemotherapyboard.org/publications

This group of individuals will also require a booster dose to extend protection from their primary course. Boosters are expected to be required from six months after the third dose, although JCVI will advise on optimal timing after evidence from trials in these populations become available.
Box: Criteria for a third primary dose of COVID-19 vaccine

Individuals with primary or acquired immunodeficiency states at the time of vaccination due to conditions including:

- acute and chronic leukaemias, and clinically aggressive lymphomas (including Hodgkin’s lymphoma) who were under treatment or within 12 months of achieving cure at the time of vaccination
- individuals under follow up for a chronic lymphoproliferative disorders including haematological malignancies such as indolent lymphoma, chronic lymphoid leukaemia, myeloma, Waldenstrom’s macroglobulinemia and other plasma cell dyscrasias (Note: this list is not exhaustive)
- adults and children aged 12 years and over with immunosuppression due to HIV/AIDS with a current CD4 count of <200 cells/µl
- Primary or acquired cellular and combined immune deficiencies – those with lymphopaenia (<1,000 lymphocytes/µl) or with a functional lymphocyte disorder
- those who had received an allogeneic (cells from a donor) or an autologous (using their own cells) stem cell transplant in the 24 months before vaccination
- those who had received a stem cell transplant more than 24 months before vaccination but had ongoing immunosuppression or graft versus host disease (GVHD)
- persistent agammaglobulinaemia (IgG < 3g/L) due to primary immunodeficiency (e.g. common variable immunodeficiency) or secondary to disease / therapy

Individuals on immunosuppressive or immunomodulating therapy at the time of vaccination including:

- those who were receiving immunosuppressive therapy for a solid organ transplant at the time of vaccination
- those who were receiving or had received in the previous 3 months targeted therapy for autoimmune disease, such as JAK inhibitors or biologic immune modulators including B-cell targeted therapies (including rituximab but in this case the recipient would be considered immunosuppressed for a 6 month period), T-cell co-stimulation modulators, monoclonal tumour necrosis factor inhibitors (TNFi), soluble TNF receptors, interleukin (IL)-6 receptor inhibitors, IL-17 inhibitors, IL 12/23 inhibitors, IL 23 inhibitors. (Note: this list is not exhaustive)
- those who were receiving or had received immunosuppressive chemotherapy or radiotherapy for any indication in the 6 months before vaccination

Individuals with chronic immune-mediated inflammatory disease who were receiving or had received immunosuppressive therapy prior to vaccination including:

- high dose corticosteroids (equivalent to ≥ 20mg prednisolone per day) for more than 10 days in the month before vaccination
- long term moderate dose corticosteroids (equivalent to ≥10mg prednisolone per day for more than 4 weeks) in the 3 months before vaccination
- non-biological oral immune modulating drugs, such as methotrexate >20mg per week (oral and subcutaneous), azathioprine >3.0mg/kg/day, 6-mercaptopurine >1.5mg/kg/day, mycophenolate >1g/day) in the 3 months before vaccination
- certain combination therapies at individual doses lower than above, including those on ≥7.5mg prednisolone per day in combination with other immunosuppressants (other than hydroxychloroquine or sulfasalazine) and those receiving methotrexate (any dose) with leflunomide in the 3 months before vaccination

Individuals who had received high dose steroids (equivalent to >40mg prednisolone per day for more than a week) for any reason in the month before vaccination
Reinforcing immunisation

JCVI have advised that adults who received a primary course in Phase 1 of the COVID-19 vaccination programme (priority groups 1-9) should be offered a COVID-19 booster vaccine. This includes:

- those living in residential care homes for older adults
- all adults aged 40 years or over
- frontline health and social care workers
- all those aged 16 to 49 years with underlying health conditions that put them at higher risk of severe COVID-19 (table 3)
- adult carers and those experiencing homelessness
- adult household contacts of immunosuppressed individuals

The JCVI is recommending that booster vaccines are scheduled at a six month interval from completing the primary course. This interval will automatically help to prioritise older and more vulnerable patients.

For operational reasons, administration may be brought forward to a minimum of five months in certain circumstances including:

- in a care home setting to enable all residents to be vaccinated in the same session
- where an otherwise eligible individual attends for another reason (for example to receive influenza vaccine)

For those about to receive immunosuppressive treatment where the booster may be brought forward to a minimum of four months (~120 days) to avoid giving the booster when the immune system is less able to respond. Third doses given to those who were severely immunosuppressed at/around the time of their first or second primary dose do not count as booster doses. These individuals are expected to also require a booster after another six months, but JCVI will review evidence from trials of boosting in this population and issue further advice on the optimal timing for this group.

In general, individuals under 40 years of age may be expected to generate more durable immunity from primary vaccination compared to older individuals and will have only received their second COVID-19 vaccine dose in late summer or early autumn. Advice on reinforcing doses for younger people, including children under 16 years and healthy pregnant women are therefore under further consideration.

Age specific recommendations on vaccine type

Children under 16 and young adults aged 16-17 years

The Pfizer BioNTech vaccine (Comirnaty®) has approval for use from 12 years old and currently has the most extensive safety data in those aged 12-17 years. This vaccine is therefore the preferred vaccine for children and young people. Although Moderna vaccine is also approved in children, Pfizer is currently preferred due to a lower reported rate of myocarditis.\(^1\) Young people who have had a first dose of AstraZeneca vaccine, and are eligible for a second dose, should complete with the same vaccine (see contraindications and precautions).

Healthy adults aged 18-39 years
Evidence suggests that the risk of serious COVID-19 disease is strongly related to age, and the risk of COVID-19 mortality, hospitalisation and ICU admission is lower in younger adults. Based on the current epidemiological situation, and taking into account projected vaccine supply, JCVI are advising a preference for a vaccine other than AstraZeneca to be offered to healthy people under 40 years of age, including health and social care workers, unpaid carers and household contacts of immunosuppressed individuals. This advice may change if there is a change in the epidemiology or an interruption in the supply of the alternative vaccines. Within this age group, those who are older (over 30 years of age), male, from certain minority ethnic backgrounds, in certain occupations at high risk of exposure, and those who are obese, remain at high risk of COVID-19. In the absence of a suitable alternative these individuals should still be offered the AstraZeneca vaccine, and may choose to receive the vaccine, provided they have been informed and understand the relative risks and benefits. They should be given the latest version of the COVID-19 vaccination and blood clotting leaflet (https://www.gov.uk/government/publications/covid-19-vaccination-and-blood-clotting). Those who have already received a dose of AstraZeneca vaccine should complete with the same vaccine (see contraindications and precautions).

Aged 40 years and over or in high risk groups
Individuals aged 40 years and over, those who are clinically extremely vulnerable and those in clinical risk groups (see table 3) are at high risk of the complications of COVID-19. The JCVI, MHRA and WHO consider that any risk from the rare side effects seen after AstraZeneca vaccine are outweighed by the benefits of vaccination. These individuals can therefore be offered vaccination with any of the available products, unless otherwise contra-indicated.

Pregnant women in eligible groups
Pfizer and Moderna vaccines are the preferred vaccines for eligible pregnant women (for those under 18, Pfizer BioNTech vaccine (Comirnaty®) is preferred), because of more extensive experience of their use in pregnancy. Pregnant women who commenced vaccination with AstraZeneca, however, are advised to complete with the same vaccine (see section on pregnancy). If completion with AstraZeneca is not possible or that vaccine is not considered suitable, completion with Pfizer BioNTech vaccine can be considered with appropriate counselling.

Third primary doses for those aged 12 years and over with severe immunosuppression
For those aged over 18 years, JCVI advises a preference for mRNA vaccines - Pfizer BioNTech (Comirnaty®) or Moderna (Spikevax®) - for the third primary dose. Pfizer BioNTech (Comirnaty®) is preferred for 12-17 year olds. AstraZeneca COVID-19 vaccine (Vaxzevria®) is an option for individuals who have received this vaccine previously where this would help to improve implementation. In exceptional circumstances, persons aged 40 years or over who received a mRNA COVID-19 vaccine previously may be offered a third dose of AstraZeneca Vaxzevria vaccine following a decision by a health professional on a case-by-case basis.

Reinforcing vaccination
Based on an unpublished study of immunogenicity and reactogenicity in those primed with different vaccines in the UK, the committee advised that the Pfizer-BioNTech vaccine should be offered as a booster dose irrespective of the vaccine used for the primary course. Although no comparative studies are available, the committee agreed that a half dose
(50µg) of the Moderna COVID-19 vaccine is a suitable alternative as it gives good immune responses in those primed with Moderna and is expected to have a lower rate of side effects (including myocarditis) than a full dose (Choi et al, 2021).

Where mRNA vaccines are not suitable, for example domiciliary vaccination for housebound patients, AstraZeneca vaccine may be considered in those who had received at least one dose of this vaccine previously. In exceptional circumstances, persons aged 40 years or over who received a mRNA COVID-19 vaccine previously may be offered a booster dose of AstraZeneca Vaxzevria vaccine following a decision by a health professional on a case-by-case basis.

Other considerations

Previous incomplete vaccination

If the course is interrupted or delayed, it should be resumed using the same vaccine but the first dose should not be repeated. Evidence suggests that those who receive mixed schedules, including mRNA and adenovirus vectored vaccines make a good immune response, (Liu et al, 2021) although rates of side effects with a heterologous second dose are higher. (Shaw et al, 2021). Therefore, every effort should be made to determine which vaccine the individual received and to complete the primary course with the same vaccine. For individuals who started the schedule and who attend for vaccination where the same vaccine is not considered suitable or if the first product received is unknown or not available, it is reasonable to offer one dose of the locally available product to complete the primary course. This option is preferred if the individual is likely to be at immediate high risk or is considered unlikely to attend again.

Individuals who experience severe expected reactions after a first dose of AstraZeneca or Pfizer vaccines appear to have a higher rate of such reactions when they receive a second dose of the alternate vaccine. (Powell et al, 2021). Therefore, individuals who have received a first dose of the AstraZeneca vaccine should normally complete the primary course with the same vaccine, with the exception of those who experienced an episode of anaphylaxis, thrombosis and thrombocytopenia syndrome or GBS (see contra-indications and precautions).

Individuals who have participated in a clinical trial of COVID-19 vaccines should be provided with written advice on whether and when they should be safely vaccinated in the routine programme. Advice should also be provided from the trial investigators on whether any individual could receive additional doses for the purposes of vaccine certification. Trial participants who are eligible for boosters should be offered vaccination in line with the general population, six months after the dose considered as the final primary dose or the final revaccination (if the latter is required for certification purposes).

Individuals who have been vaccinated abroad are likely to have received an mRNA or vector vaccine based on the spike protein, or an inactivated whole viral vaccine. Specific advice on Vaccination of those who received COVID-19 vaccine overseas is available from UKHSA. https://www.gov.uk/government/publications/covid-19-vaccinations-received-overseas

Co-administration with other vaccines

Although no data for co-administration of COVID-19 vaccine with other vaccines exists, in the absence of such data first principles would suggest that interference between inactivated vaccines with different antigenic content is likely to be limited (see Chapter 11). Based on experience with other vaccines, any potential interference is most likely to result in a slightly
attenuated immune response to one of the vaccines. There is no evidence of any safety concerns, although it may make the attribution of any adverse events more difficult. Similar considerations apply to co-administration of inactivated (or non-replicating) COVID-19 vaccines with live vaccines such as MMR. In particular, live vaccines which replicate in the mucosa, such as live attenuated influenza vaccine (LAIV) are unlikely to be seriously affected by concomitant COVID-19 vaccination.

As all of the early COVID-19 vaccines are considered inactivated (including the non-replicating adenovirus vaccine), where individuals in an eligible cohort present having recently received one or more inactivated or another live vaccine, COVID-19 vaccination should still be given. The same applies for most other live and inactivated vaccines where COVID-19 vaccination has been received first or where a patient presents requiring two or more vaccines. It is generally better for vaccination to proceed to avoid any further delay in protection and to avoid the risk of the patient not returning for a later appointment. This includes but is not limited to vaccines commonly administered around the same time or in the same settings (including influenza and pneumococcal polysaccharide vaccine in those aged over 65 years, pertussis-containing vaccines and influenza vaccines in pregnancy, and LAIV, HPV, MenACWY and Td-IPV vaccines in the schools programmes). The only exceptions to this are the shingles vaccines, where a seven day interval should ideally be observed. This is based on the potential for an inflammatory response to COVID-19 vaccine to interfere with the response to the live virus in the older population and because of the potential difficulty of attributing systemic side effects to the newer adjuvanted shingles vaccine.

A UK study of co-administration of AstraZeneca and Pfizer BioNTech COVID-19 vaccines with inactivated influenza vaccines confirmed acceptable immunogenicity and reactogenicity (Lazarus et al., 2021). Where co-administration does occur, patients should be informed about the likely timing of potential adverse events relating to each vaccine. If the vaccines are not given together, they can be administered at any interval, although separating the vaccines by a day or two will avoid confusion over systemic side effects.

Monoclonal antibodies to COVID-19 have recently been licensed for the treatment and prophylaxis of COVID-19 infection. Primate data suggests that administration of the AstraZeneca combination monoclonal antibody product did not interfere with the subsequent response to active vaccination. Based on this limited evidence, therefore, no specific interval is required between receipt of these products and COVID-19 vaccination, or vice versa. As the use of these products is likely to be prioritised to those who are less able to respond to vaccination, for example immunosuppressed individuals, additional doses of vaccine may be required as outlined above.

Specific population groups

Pregnancy

There is no known risk associated with giving inactivated, recombinant viral or bacterial vaccines or toxoids during pregnancy or whilst breastfeeding (Kroger et al., 2013). Since inactivated vaccines cannot replicate, they cannot cause infection in either the mother or the fetus. Although AstraZeneca COVID-19 vaccine contains a live adenovirus vector, this virus is not replicating so will not cause infection in the mother or the fetus. As with most pharmaceutical products, large clinical trials of COVID-19 vaccine in pregnancy have not been carried out.

Developmental and reproductivity testing of the Pfizer BioNTech, Moderna and AstraZeneca vaccines in animals have not raised any concerns. Adenovirus vectors, similar to those used in
the AstraZeneca COVID-19 vaccine, have been widely used to vaccinate women against Ebola without raising any concern; formal trials of these vaccines in pregnancy are due to proceed.

Although clinical trials on the use of COVID-19 vaccines during pregnancy are not advanced, the available data do not indicate any harm to pregnancy. JCVI has therefore advised that women who are pregnant should be offered primary and reinforcing immunisation at the same time as non-pregnant women, based on their age and clinical risk group. There is extensive post-marketing experience of the use of the Pfizer BioNTech and Moderna vaccines in the USA with no safety signals so far.\(^1\) Over 80,000 women now report having been vaccinated whilst pregnant or when they might be pregnant in England. Because of wider experience with mRNA vaccines, these are currently the preferred vaccines to offer to pregnant women. Clinicians should discuss the risks and benefits of vaccination with the woman, who should be told about the limited evidence of safety for the vaccine in pregnancy.

Routine questioning about last menstrual period and/or pregnancy testing is not required before offering the vaccine. Women who are planning pregnancy or in the immediate postpartum should be vaccinated with a suitable product for their age and clinical risk group.

If a woman finds out she is pregnant after she has started a course of vaccine, she should complete vaccination during pregnancy using the same vaccine product (unless contra-indicated).

Termination of pregnancy following inadvertent immunisation should not be recommended. Surveillance of the inadvertent administration of COVID-19 vaccines in early pregnancy is being conducted for the UK by the UK Health Security Agency Immunisation and Vaccine Preventable Diseases Division, to whom such cases should be reported.\(^2\) As above, women who are inadvertently vaccinated in early pregnancy should be offered the second dose of the same product.

**Breastfeeding**

There is no known risk associated with being given a non-live vaccine whilst breastfeeding. JCVI advises that breastfeeding women should be offered any suitable COVID-19 vaccine. Emerging safety data is reassuring: mRNA was not detected in the breast milk of recently vaccinated women (Golan et al, 2021) and protective antibodies have been detected in breast milk (Gray et al, 2021)


The developmental and health benefits of breastfeeding are clear and should be discussed with the woman, along with her clinical need for immunisation against COVID-19.

**Children**

SARS-CoV-2 vaccine trials have been conducted in those aged 12-15 years for both Pfizer and Moderna vaccines, and more safety and immunogenicity data are emerging. Children and young people have a very low risk of COVID-19, severe disease or death due to SARS-CoV-2 compared to adults and so JCVI has not recommended routine COVID-19 vaccination for children and young people under 16 years of age. The Chief Medical Officers, however, have recommended vaccination for school children aged 12-15 to help avoid school absences and disruption to face-to-face education.\(^3\)

---

Children under 16 years of age are at low risk of COVID-19 mortality, and risk of hospital admission is largely confined to those in clinical risk groups. Some children, such as those with profound and multiple LD (PMLD) and severe LD, and including children with Down’s syndrome and cerebral palsy are at higher risk of hospitalisation for COVID-19 (Williamson et al, 2021). Analysis undertaken by an expert group recently concluded that rates of intensive care admission exceeded 100 per million over the first year of the pandemic in children with a broad range of underlying conditions. Children aged over 12 years with these conditions are therefore recommended to have a full course of COVID-19 vaccines (see above and table 4).

**Immunosuppression and HIV**

Individuals who have immunosuppression and HIV infection (regardless of CD4 count) should be given COVID-19 vaccine in accordance with the recommendations and contraindications above. Although AstraZeneca COVID-19 vaccine contains a live adenovirus vector, this virus is not replicating and is considered safe in immunosuppressed people. Other adenovirus vector vaccines have been trialled in populations with high prevalence of HIV and shown no serious adverse events (Kennedy et al, 2017). Although individuals with stable treated HIV infection were not excluded from the phase 3 trial of the Pfizer and Moderna mRNA vaccines, data on safety and effectiveness in this group have not been presented. A study of the AstraZeneca vaccines in people living with HIV infection is underway.

Individuals with immunosuppression may not make a full immune response to vaccination. As there is limited evidence on the response in immunosuppressed individuals there is also very little evidence upon which to base advice on the optimal timing of delivery. A recent study suggested immune responses were better, however, in patients with cancer who received their chemotherapy at least two weeks earlier (Monin-Aldama et al, 2021). Specialists may advise their patients based on their knowledge and understanding of their immune status and likely immune response to vaccination, but should also consider the risk from COVID-19 and the patient’s likelihood of exposure. The small number of patients who are about to receive planned immunosuppressive therapy should be considered for vaccination prior to commencing therapy (ideally at least two weeks before), when their immune system is better able to make a response. Where possible, it would also be preferable for the 2-dose schedule to be completed prior to commencing immunosuppression. This would entail offering the second dose at the recommended minimum for that vaccine (three or four weeks from the first dose) to provide maximum benefit that may not be received if the second dose was given during the period of immunosuppression. Any decision to defer immunosuppressive therapy or to delay possible benefit from vaccination until after therapy should not be taken without due consideration of the risks from COVID-19 and from their underlying condition.

Emerging evidence suggests that many patients with immunosuppression are protected after two doses of vaccination. (Whitaker et al, 2021). Individuals aged 12 years or over who are household contacts of immunosuppressed patients of any age should be offered vaccine to reduce the risks of exposure.

Despite the overall reassuring evidence, some individuals with more severe immunosuppression do not make a good immune response to a complete primary course of vaccine and may therefore remain at high risk. This includes, but is not limited to, individuals on immunosuppression for solid organ transplants (Prendecki et al 2021), those with haematological cancers who are within six months of completing curative therapy.
(Lim et al, 2021), and those on certain monoclonal antibody therapies (Mahil et al, 2021). Post-vaccination testing for spike antibody may therefore be considered by specialists managing individuals with severe immunosuppression. Individuals can then be advised whether to take precautions to reduce their chance of exposure, taking into account their underlying immune defect and any test results. Although the immune correlates of protection are currently unknown, antibody levels taken 28-42 days after the second dose may be reassuring if positive and/or similar to those seen with the same assay used in immunocompetent older individuals. Low levels of detectable antibody may indicate poor protection against mild infection, although protection against severe disease may still be present due to T and B cell immunological memory.

Individuals who have received a bone marrow transplant after vaccination should be considered for a re-immunisation programme for all routine vaccinations and for COVID-19 (see chapter 7). JCVI has also recommended that individuals with severe immunosuppression (Box) should be offered a third primary dose of vaccine (see above).

**Contraindications**

There are very few individuals who cannot receive the Pfizer BioNTech, Moderna or AstraZeneca COVID-19 vaccines. Where there is doubt, rather than withholding vaccination, appropriate advice should be sought from the relevant specialist, or from the local immunisation or health protection team.

The following are relative contra-indications to receiving a COVID-19 vaccine:

- **individuals who have had a previous systemic anaphylaxis reaction to a COVID-19 vaccine**
  - individuals who received Astra-Zeneca vaccine may be given an alternate vaccine in any setting, with observation for 30 minutes
  - there is now evidence that many individuals with initial apparent allergic reaction to an mRNA vaccine can tolerate a second dose of the same vaccine. Where there were no objective signs of anaphylaxis and symptoms rapidly resolved (with no more than 1 dose of IM adrenaline), a further dose of the same vaccine can be given in any vaccination setting. If the reaction might have been anaphylaxis, obtain expert advice; if a decision is made to administer the same vaccine, then this should be done under medical supervision in the hospital setting. See flowchart, page 31 for further information.

- **individuals with a prior allergic reaction to any component (excipient) of the COVID-19 vaccine e.g. polyethylene glycol**
  - published data now show that some individuals with prior allergic reaction to PEG-containing medicines (eg. PEG-asparaginase) can tolerate the PfizerBioNTech vaccine (although the historical reaction may have been due a non-PEG component) (Mark et al, 2021). Expert advice should be obtained and if a decision is made to administer an mRNA vaccine, then this should only be done in hospital under medical supervision.

**Precautions**

Minor illnesses without fever or systemic upset are not valid reasons to postpone immunisation. If an individual is acutely unwell, immunisation may be postponed until they have fully recovered. This is to avoid confusing the differential diagnosis of any acute illness (including COVID-19) by wrongly attributing any signs or symptoms to the adverse effects of the vaccine.
There is no convincing evidence of any safety concerns from vaccinating individuals with a past history of COVID-19 infection, or with detectable COVID-19 antibody.

Vaccination of individuals who may be infected or asymptomatic or incubating COVID-19 infection is unlikely to have a detrimental effect on the illness. Vaccination should be deferred in those with confirmed infection to avoid confusing the differential diagnosis. As clinical deterioration can occur up to two weeks after infection, vaccination of adults and high risk children should be deferred until clinical recovery to around four weeks after onset of symptoms or four weeks from the first confirmed positive specimen in those who are asymptomatic. In younger people, protection from natural infection is likely to be high for a period of months, and vaccination in those recently infected may increase the chance of side effects. Therefore vaccination should ideally be deferred till at least twelve weeks from onset (or sample date) in children and young people under 18 years who are not in high risk groups. This includes children and young people who developed PIMS-TS in association with COVID-19 infection and then become eligible for vaccination. Current advice in PIMS-TS cases suggests that an interval of 12 weeks should be observed, although earlier administration can be considered in those at risk of infection and/or who are fully recovered.

Having prolonged COVID-19 symptoms is not a contraindication to receiving COVID-19 vaccine but if the patient is seriously debilitated, still under active investigation, or has evidence of recent deterioration, deferral of vaccination may be considered to avoid incorrect attribution of any change in the person's underlying condition to the vaccine.

**Individuals with a history of allergy**

A very small number of individuals have experienced anaphylaxis when receiving a COVID-19 vaccine. Anyone with a history of allergic reaction to an excipient in the COVID-19 vaccine should not receive that vaccine (except with expert advice), but those with any other allergies (such as a food allergy) – including those with prior anaphylaxis – can have the vaccine.

The Pfizer BioNTech and Moderna mRNA vaccines contain polyethylene glycol (PEG). PEGs (also known as macrogols) are a group of known allergens commonly found in medicines, many household products and cosmetics. Medicines containing PEG include some tablets, laxatives, depot steroid injections, and some bowel preparations used for colonoscopy. Known allergy to PEG is rare but has been implicated in a minority of allergic reactions reported.

All recipients of the Pfizer BioNTech and Moderna vaccines should be kept for observation and monitored for a minimum of 15 minutes. Facilities for management of anaphylaxis should be available at all vaccination sites (see chapter 8). Advice has also been issued by the Resuscitation Council.¹

The rate of anaphylaxis reported to date after the AstraZeneca vaccine is in line with the expected rate of anaphylaxis to non-COVID vaccines. The AstraZeneca vaccine does not contain PEG but does contain a related compound called polysorbate 80. Rarely, people with PEG allergy may also be allergic to polysorbate 80. However, polysorbate 80 is widely used in medicines and foods, and is present in many medicines including monoclonal antibody preparations. Some injected influenza vaccines (including the main vaccine used in over 65 year olds) contain polysorbate 80. Individuals who have tolerated injections that contain polysorbate 80 (including the adjuvanted influenza vaccine, Fluad® and the GlaxoSmithKline vaccine Fluarix®) are likely to tolerate the AstraZeneca vaccine. Advice on the management of patients with allergy is summarised in table 5.

Table 5: Management of patients with a history of allergy

<table>
<thead>
<tr>
<th>PATIENT CHARACTERISTICS</th>
<th>ACTIONS</th>
<th>VACCINATION CONTRA-INDICATED</th>
</tr>
</thead>
<tbody>
<tr>
<td>● previous allergic reaction (including anaphylaxis) to a food, insect sting and most medicines (where trigger has been identified)</td>
<td>● proceed with vaccination as normal, according to local guidelines</td>
<td>● prior anaphylaxis reaction to COVID-19 vaccine</td>
</tr>
<tr>
<td>● family history of allergies</td>
<td></td>
<td>● prior systemic allergic reaction to a component of the vaccine (for known PEG allergy see text above)</td>
</tr>
<tr>
<td>● previous non-systemic reaction to a vaccine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>● hypersensitivity to non-steroidal anti-inflammatory drugs e.g. aspirin, ibuprofen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>● mastocytosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>● consider possibility of PEG allergy and seek allergy advice if needed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>● consider observation for 30 minutes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>● some patients may benefit from pretreatment with antihistamine, however this may mask initial symptoms of a reaction</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patients with undiagnosed PEG allergy often have a history of immediate onset-unexplained anaphylaxis or anaphylaxis to multiple classes of drugs or an unexplained anaphylaxis. Such individuals should not be vaccinated with the Pfizer BioNTech or Moderna vaccines, except on the expert advice of an allergy specialist. The AstraZeneca vaccine can be used as an alternative (unless otherwise contraindicated), particularly if they previously tolerated the adjuvanted influenza vaccine. The vaccine should be administered in a setting with full resuscitation facilities (e.g. a hospital), and a 30 minute observation period is recommended. Advice for children with cancer who may be receiving PEG containing drugs is available at [https://www.cclg.org.uk/Coronavirus-advice](https://www.cclg.org.uk/Coronavirus-advice).

The British Society for Allergy and Clinical Immunology (BSACI) has advised that individuals who have a reaction to the first dose of a COVID-19 vaccine may be able to receive a second dose of vaccine, as in the flowchart below. Many individuals have tolerated subsequent doses of the same vaccine, and this is preferred as it avoids an individual being wrongly labelled as allergic for life.

Individuals with non-allergic reactions (vasovagal episodes, non-urticarial skin reaction or non-specific symptoms) to the first dose of a COVID-19 vaccine can receive the second dose of vaccine in any vaccination setting.
Flowchart for managing patients who have allergic reactions to a previous dose of COVID-19 vaccine

Did symptoms begin within 2 hours of vaccination?

No

Delayed urticaria/angioedema

- Reaction self-limiting or resolved with oral antihistamine
  - Can have further dose using the same vaccine in any vaccination setting.¹

Yes

Immediate-type allergic reaction

- Systemic symptoms but no objective symptoms of anaphylaxis:
  - no respiratory or cardiovascular compromise
  - symptoms rapidly resolved with maximum 1 dose of IM adrenaline
  - Can have further dose using the same vaccine, in any vaccination setting. Observe for at least 30mins.¹

- Anaphylaxis: i.e. objective respiratory and/or cardiovascular compromise, usually with skin signs
  - Seek advice from Allergy Specialist:
    - Many individuals do not react when given a dose of the same vaccine
    - Give further dose with same vaccine in hospital setting
    - OR
    - Give alternative² vaccine for further dose.
    - Observe for at least 30mins.¹

¹ Consider pre-treatment with non-sedating antihistamine, at least 30mins prior to vaccination
² If reaction was to AstraZeneca vaccination, complete or boost with an mRNA vaccine. If reaction was to an mRNA vaccine, give the same or alternative mRNA vaccine in hospital setting.
Thrombosis and thrombocytopenia syndrome (TTS) occurring after COVID-19 vaccination

A recently recognised condition involving serious thromboembolic events accompanied by thrombocytopenia, has been reported after AstraZeneca vaccination.

There is no evidence of any underlying risk factors in the individuals affected by this condition who have mainly been previously healthy. The condition is rare, tends to present with unusual forms of clotting and the mechanism is believed to be an idiosyncratic reaction related to an immune response to the AstraZeneca vaccine. This may be related to the recipient’s polymorphisms in genes encoding Fc receptors in the immune system and is an area of active research. Because of this likely immune mechanism, there is no reason to believe that individuals with a past history of clots or of certain thrombophilic conditions would be at increased risk of this very rare condition. Similarly, although pregnancy increases the risk of clotting conditions, there is no evidence that pregnant women, those in the post-partum or women on the contraceptive pill are at higher risk of the specific condition of thrombosis in combination with thrombocytopenia after the AstraZeneca vaccine. There have been no confirmed cases reported in pregnant women to date. Caution should be used, however, when vaccinating individuals who have a history of a previous episode of heparin induced thrombocytopenia and thrombosis (HITT or HIT type 2).

Individuals who experience a clotting episode with concomitant thrombocytopenia following the first dose of AstraZeneca vaccine should be properly assessed. If they are considered to have the reported condition, further vaccination should be deferred until their clotting has completely stabilised. A number of patients with confirmed TTS in the UK have tolerated a second dose of Pfizer BioNTech (n=23), Moderna (n=2) and AstraZeneca (n=1) vaccine, given between 10 and 18 weeks after the first dose. A recent study documented decline in anti-PF4 antibody by 12 weeks following the first dose of vaccine; follow up of 5 patients with confirmed TTS who received Pfizer BioNTech for the second dose at a minimum interval of 10 weeks had no further episodes (Schönborn et al, 2021). Current evidence would therefore support a decision to complete the primary course or boost patients with a history of TTS with an mRNA vaccine, provided at least 12 weeks has elapsed from the implicated dose.

Individuals who have received the first dose of AstraZeneca vaccine without developing this rare condition are advised to receive the second dose of the same vaccine at the currently recommended interval. To date, there is no signal of an increased risk of this condition after the second dose and the rate of other reactions is lower at the second dose than after the first dose of this vaccine. Using an alternative product for the second dose is more likely to lead to common side effects.

Based on current evidence JCVI is advising a preference for an alternative vaccine for healthy people under 40 years of age, including health and social care workers, unpaid carers and household contacts of immunosuppressed individuals.

Individuals with past clotting episodes and those diagnosed with thrombophilia, whether or not they are on long term anti-coagulation, remain at risk of COVID-19 disease. There is no evidence that those with a prior history of thrombosis or known risk factors for thrombosis are more at risk of developing this immune-mediated condition of thrombosis in combination with thrombocytopenia after the AstraZeneca vaccine. For most of these individuals, the risk of recurrent thrombosis due to COVID-19 infection, remains far greater than the risk of this syndrome. Therefore individuals aged 40 years and over with such a
history should be vaccinated with any of the available vaccines (provided they are not otherwise contra-indicated). The same consideration applies to those who experience common clotting episodes after the first dose of AstraZeneca vaccine but without concomitant thrombocytopaenia.

**Other rare conditions**

Cases of myocarditis and pericarditis have been reported rarely after COVID-19 vaccination. If an individual develops myocarditis or pericarditis following the first COVID-19 vaccination they should be assessed by an appropriate clinician to determine whether it is likely to be vaccine related. As the mechanism of action and risk of recurrence of myocarditis and pericarditis are being investigated, the current advice is that an individual’s second or subsequent doses should be deferred pending further investigation. For those that experience myocarditis or pericarditis within two weeks of the first dose of an mRNA vaccine, testing for N antibody may indicate prior exposure to COVID-19. These individuals are likely to be well protected and therefore the benefit from a second dose is likely to be more limited. Where N antibody is negative or in other circumstances where a full course is considered necessary, a second dose of Pfizer vaccine can be considered once the patient has fully recovered. Emerging evidence suggests that an interval of at least 12 weeks should be observed and Pfizer is preferred over Moderna due to a slightly higher rate of myocarditis reported after the latter vaccine; AstraZeneca should not be offered to those who have previously received an mRNA vaccine given the more serious nature of thrombosis and thrombocytopaenia syndrome. Similar considerations apply to individuals who experience myocarditis after the second dose, where boosting with Pfizer may be considered for those at higher risk of the complications of COVID-19 infection.

Very rare reports have been received of GBS following COVID-19 vaccination, so healthcare professionals should be alert to the signs and symptoms of GBS to ensure correct diagnosis and to rule out other causes, in order to initiate adequate supportive care and treatment.

Individuals who have a history of GBS should be vaccinated as recommended for their age and underlying risk status. Cases of GBS reported following vaccination may occur by chance (the background rate of GBS is 2 per 100,000 per year in the population) and no causal mechanism with COVID-19 vaccination has been proven. There is evidence to suggest that having had a prior diagnosis of GBS does not predispose an individual to further episodes of GBS when immunised with other vaccines (Baxter et al., 2012) and for the Pfizer BioNTech COVID-19 vaccine (Ben David et al., 2021). In those who are diagnosed with GBS after the first dose of vaccine, the balance of risk benefit is in favour of completing a full COVID-19 vaccination schedule. On a precautionary basis, however, where GBS occurs within six weeks of an AstraZeneca vaccine, for any future doses Pfizer or Moderna COVID-19 vaccines are preferred. Where GBS occurs following either of the mRNA vaccines, further vaccination can proceed as normal, once recovered.

Extremely rare reports of capillary leak syndrome have been reported after AstraZeneca vaccine in individuals with a prior history of this condition. Individuals with a history of capillary leak syndrome, should be carefully counselled about the risks and benefits of vaccination and may be offered an alternative product.
Reporting anaphylaxis and other allergic reactions

Anaphylaxis is a very rare, recognised side effect of most vaccines and suspected cases should be reported via the Coronavirus Yellow Card Scheme (www.coronavirus-yellowcard.mhra.gov.uk). Chapter 8 of the Green Book gives detailed guidance on distinguishing between faints, panic attacks and the signs and symptoms of anaphylaxis. If a case of suspected anaphylaxis meets the clinical features described in Chapter 8, this should be reported via the Yellow Card Scheme as a case of ‘anaphylaxis’. Cases of less severe allergic reactions (i.e. not including the clinical features of anaphylaxis) should not be reported as anaphylaxis but as ‘allergic reaction’.

As these vaccines are labelled with a black triangle, all adverse reactions occurring in individuals of any age after vaccination should be reported to the MHRA using the Yellow Card Scheme. Anyone can report a suspected adverse reaction to the Medical and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme (www.yellowcard.gov.uk). Any adverse reaction should also be documented in accordance with local procedures.

Management of suspected cases and contacts

There is currently limited evidence to support the use of COVID-19 vaccines as post-exposure prophylaxis or to interrupt transmission during outbreaks. The use of vaccine to provide direct protection to vulnerable individuals in prolonged community outbreaks should be discussed with the local health protection teams.

Current recommendations for testing and contact tracing and guidance on infection control is regularly updated and can be found in the following links:

https://www.gov.uk/coronavirus
https://www.hps.scot.nhs.uk/a-to-z-of-topics/covid-19/

Additional resources

Supplies
COVID-19 vaccines for those authorised by the NHS to deliver the programme will be made available for ordering on the ImmForm website https://portal.immform.phe.gov.uk/ telephone 0207 183 8580.

Arrangements in Scotland, Wales and Northern Ireland may be different, please contact Public Health Agencies in each respective administration for local details.

Key links
The full specification for those diagnoses, and associated clinical codes, eligible for COVID-19 vaccination has been developed and is available on the PRIMIS website https://www.nottingham.ac.uk/primis/covid-19/covid-19.aspx. Access to the link is available to NHS professionals and requires online registration.
References


Chapter 14a - COVID-19 - SARS-CoV-2

Golan Y, Prahl M, Cassidy A et al. COVID-19 mRNA vaccine is not detected in human milk. https://www.medrxiv.org/content/10.1101/2021.03.05.21252998v1.full.pdf


Harwood R, Yan H, Talawila Da Camara N. Which children and young people are at higher risk of severe disease and death after SARS-CoV-2 infection: a systematic review and individual patient meta-analysis. https://doi.org/10.1101/2021.06.30.21259763


Lim SH, Campbell N, Johnson M et al. Antibody response after SARS-CoV-2 vaccination in lymphoma. https://www.medrxiv.org/content/10.1101/2021.06.05.21258311v1


Morin-Aldama L, Laing AG, Muñoz-Ruiz M. Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines. https://doi.org/10.1101/2021.03.17.21253131


Shrotri M, Krutikov M, Palmer T et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study). medRxiv [preprint], doi: 10.1101/2021.03.26.21254391

Smith C, Odd D, Harwood R et al. Deaths in Children and Young People in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data. 10.21203/rs.3.rs-689684/v1


Tenforde MW Self WH, Naioti EA, et al. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March—July 2021. MMWR 70(34);1156-1162. https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e2.htm?s_cid=mm7034e2_w


Vousden N, Bunch K, Morris E MD. The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and 2 asymptomatic SARS-CoV-2 infection in the UK from March to September 2020: a national cohort 3 study using the UK Obstetric Surveillance System (UKOSS). https://www.medrxiv.org/content/10.1101/2021.01.04.21249195v1


